Exploring Analyst Estimates for Danaher (DHR) Q3 Earnings, Beyond Revenue and EPS

Core Insights - Danaher (DHR) is expected to report quarterly earnings of $1.56 per share, reflecting a year-over-year decline of 22.8% [1] - Revenue projections stand at $5.59 billion, down 18.6% from the same quarter last year [1] - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating stability in analyst forecasts [1] Sales Estimates - The consensus estimate for 'Total sales- Diagnostics' is $2.19 billion, representing a decrease of 2.6% from the prior year [2] - 'Total sales- Life Sciences' is projected to be $1.77 billion, indicating an increase of 4% year-over-year [2] - 'Total sales- Biotechnology' is expected to reach $1.61 billion, reflecting a decline of 3.1% from the previous year [2] Operating Profit Estimates - Analysts forecast 'Operating profit- Life Sciences' at $252.85 million, down from $313 million in the same quarter last year [3] - 'Operating profit- Biotechnology' is estimated at $392.48 million, compared to $417 million a year ago [3] - The estimated 'Operating profit- Diagnostics' is $524.51 million, down from $539 million in the prior year [3] Stock Performance - Over the past month, Danaher's shares have returned -1.4%, while the Zacks S&P 500 composite has increased by 3.8% [3] - Danaher currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the overall market in the near future [3]